相关实验视频

Updated: Jun 19, 2025

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

在接受酶替代疗法的Gaucher患者中,长期和短期的葡萄糖素 (lyso-Gb1) 动态

Pawel Dubiela^1,2, Paulina Szymanska-Rozek³, Piotr Hasinski⁴

¹Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, 15-089 Bialystok, Poland.

|July 27, 2024

概括

在高氏病 (GD) 患者中,lysoglucosylceramide (lysoglucosylceramide) (lysoglucosylceramide) (lysoglucosylceramide) (lysoglucosylceramide) (lysoglucosylceramide) (lysoglucosylceramide) (lysoglucosylceramide) (lysoglucosylceramide) (lysoglucosylceramide) (lysoglucosylceramide) (lysoglucosylceramide) (lysoglucosylceramide) (lysoglucosylceramide) (lysoglucosylceramide) (lysoglucosylceramide) (lysoglucosylceramide) (lysoglucosylceramide) (lysoglucosylceramide) (lyso-Gb1)) 在酶替代疗法 (ERT) 中显示出快速降低. 然而,它的变性表明长期监测的局限性.

科学领域:

生物化学生物化学
遗传学遗传学是一个
药理学药理学是指药理学的学科.

背景情况:

氏病 (Gaucher disease,简称GD) 是一种由GBA1基因突变引起的遗传溶酶体储存障碍.
这种缺乏导致β-葡萄糖核糖酶活性受损和葡萄糖胺的积累.
酶替代疗法 (ERT) 是管理高氏病的关键治疗方法.

研究的目的:

在接受ERT的Gaucher病患者中分析lysoglucosylceramide (lyso-Gb1) 的短期和长期动态.
评估lyso-Gb1作为监测ERT疗效的生物标志物.
研究ERT对lys-Gb1水平的直接影响.

主要方法:

在一大群GD患者中,分析了长期的lyso-Gb1水平在八年内.
在Gaucher病1型 (GD1) 和3型 (GD3) 患者之间比较lyso-Gb1的变化.
在20名GD患者中,立即在ERT给药前和30分钟后测量lys-Gb1水平.

主要成果:

八年的分析显示,lyso-Gb1水平的长期变化很小,但个体变化很高.
与GD3患者 (23%) 相比,GD1患者表现出明显更高的lysogb1变异性 (34%).
在ERT后30分钟 (p < 0.0001) 观察到lysogb1的平均17%的快速和显著降低.

结论:

由于输液后的快速变化,Lyso-Gb1显示出作为监测ERT功效的生物标志物的潜力.
干血斑点 (DBS) 测试的高个体变异性和局限性需要对临床应用进行改进.
研究结果提供了GD患者管理的见解,以及生物标志物在个性化医学中的作用.

关键词:

戈舍氏病是戈舍氏病的一种疾病.生物标志物生物标志物酶替代疗法是一种酶替代疗法.葡萄糖氨酸 (glucosylsphingosine) 是一种葡萄糖氨酸.这就是lyso-Gb1的原因.

更多相关视频

Mass Spectrometric Analysis of Glycosphingolipid Antigens

Mass Spectrometric Analysis of Glycosphingolipid Antigens

Published on: April 16, 2013

Monitoring Endoplasmic Reticulum Calcium Homeostasis Using a Gaussia Luciferase SERCaMP

Monitoring Endoplasmic Reticulum Calcium Homeostasis Using a Gaussia Luciferase SERCaMP

Published on: September 6, 2015

相关概念视频

Glucose Transporters

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:

Oligosaccharide Assembly

Oligosaccharide Assembly

Protein glycosylation starts in the ER lumen and continues in the Golgi apparatus. Glycosyltransferases catalyze the addition of sugar molecules or glycosylation of proteins. Usually, these enzymes add sugars to the hydroxyl groups of selected serine or threonine residues to form O-linked glycans or the amino groups of asparagine residues to form N-linked glycans. Different positions on the same polypeptide chain can contain differently linked glycans.
Multiple sugar molecules that may or may...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...